March 7th 2024
It was found in a recent study that the updated Moderna, Pfizer-BioNTech and Novavax COVID-19 vaccines, when combined with antiviral treatments like nirmatrelvir and molnupiravir, can significantly decrease the chances of hospitalization and death from current COVID-19 variants.
Up to half of patients infected with SARS-CoV-2 may experience symptoms lasting beyond three months post-infection, including severe fatigue, organ system-based symptoms and other persistent symptoms.